Anti-cytokine therapy in chronic destructive arthritis. by Berg, W.B. van den
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/141883
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
AA = adjuvant arthritis; AIA = antigen-induced arthritis; IL-1 = interleukin-1; IL-1ra = IL-1 receptor antagonist; MMP = matrix metalloproteinase;
NF-κB = nuclear factor-κB; OPG-L = osteoprotegerin ligand; RA = rheumatoid arthritis; SCW = streptococcal cell wall fragments; TNF = tumor
necrosis factor.
Available online http://arthritis-research.com/content/3/1/018
Introduction
Studies in well-defined animal models of arthritis make it
clear that tumor necrosis factor (TNF) is involved in early
joint swelling. However, TNF alone is neither arthritogenic
nor destructive and exerts its arthritogenic potential
through the induction of interleukin-1 (IL-1). Intriguingly,
TNF-independent IL-1 production is found in many model
situations, including pathways driven by macrophages,
T cells and immune complexes. Its relevance is underlined
by the great efficacy of anti-IL-1 therapy and a total lack of
chronic, erosive arthritis in IL-1β-deficient mice. Osteo-
clast-mediated bone erosion is stimulated by IL-1 as well
as by the combination of TNF and T-cell-derived IL-17.
Cartilage erosion is dependent on IL-1β and is greatly
enhanced in the presence of immune complexes.
Arthritogenic potency of TNF and IL-1
The synovial reaction in RA patients is characterized by
the abundance of many cytokines, chemokines and
growth factors. It is now generally accepted that TNF and
IL-1 are master cytokines in the process of chronic joint
inflammation and the concomitant erosive changes in car-
tilage and bone. Proinflammatory and destructive proper-
ties were first demonstrated in culture studies in vitro and
the arthritogenic potential of TNF and IL-1 was substanti-
ated by arthritis induction in rodents. Arthritis could be
elicited by local injection of recombinant cytokines in the
knee joint [1,2]; this observation was underlined by the
occurrence of chronic, erosive arthritis in transgenic mice
displaying general TNF overexpression [3]. Interestingly,
the dominant expression of TNF-mediated pathology in
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Abstract
Tumor necrosis factor (TNF) and interleukin-1 (IL-1) are considered to be master cytokines in chronic,
destructive arthritis. Therapeutic approaches in rheumatoid arthritis (RA) patients have so far focused
mainly on TNF, which is a major inflammatory mediator in RA and a potent inducer of IL-1; anti-TNF
therapy shows great efficacy in RA patients. However, it is not effective in all patients, nor does it fully
control the arthritic process in affected joints of good responders. Directed therapy for IL-1, with IL-1
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whether the limited effect is akin to the RA process or linked to suboptimal blocking of IL-1. Analysis of
cytokine patterns in early synovial biopsies of RA patients reveals a marked heterogeneity, with variable
staining of TNF and IL-1β, indicative of TNF-independent IL-1 production in at least some patients.
Evidence for this pathway emerged from experimental arthritises in rodents, and is summarized in this
review. If elements of the models apply to the arthritic process in RA patients, it is necessary to block
IL-1β in addition to TNF.
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joint tissues in these transgenic mice is still largely unex-
plained. More recently, further proof of arthritogenicity was
obtained from the induction of arthritis by local overexpres-
sion of cytokines in joint tissues by using viral vectors [4].
Intriguingly, IL-1 is much more potent than TNF in inducing
cartilage destruction in vivo. Tiny amounts of IL-1 are suffi-
cient to cause proteoglycan synthesis inhibition in chron-
drocytes, whereas a roughly 100–1000-fold higher dose
of TNF is needed to obtain the same effect [1]. Impor-
tantly, synergy between IL-1 and TNF has been demon-
strated [2]. Apart from potency differences, it is clear that
it is hard to measure significant TNF levels in inflamed syn-
ovial tissue or synovial fluid of RA patients and the levels
are certainly not higher than those of IL-1. Most effects
might be related to membrane-bound forms of cytokines,
which are hard to measure. In contrast, impact on articular
cartilage from synovium-derived mediators probably needs
trafficking of soluble forms. The situation might be different
at sites of pannus overgrowth, where close contact
between synovial cells and chondrocytes does occur.
A strong argument for the limited, direct role of TNF in
arthritis has emerged from elegant studies in TNF trans-
genic mice. Joint inflammation was completely arrested
when these mice were treated with antibodies against
anti-IL-1 receptor [5]. This argues that the pathology runs
through the induction of IL-1, which is the real arthrito-
genic trigger, either alone or in synergy with TNF. TNF
levels were still high after treatment with antibodies
against IL-1 receptor, which implies that TNF alone is
hardly arthritogenic.
TNF and IL-1 as therapeutic targets in arthritis
Both animal model studies and clinical observations have
contributed greatly to the identification of TNF and IL-1
as useful therapeutic targets. Apart from the obvious
demonstration that arthritis in TNF transgenic mice could
be blocked with anti-TNF antibodies, it was a major
breakthrough to note that collagen type II arthritis, the
classical RA model in rodents, could be suppressed with
anti-TNF antibodies or TNF soluble receptors [6–8]. This
identified a key role of TNF in autoimmune arthritis.
Further studies on this model revealed that TNF block-
ade was efficient when started before or shortly after the
onset of arthritis, whereas anti-IL-1 treatment was at
least as efficient and also arrested advanced arthritis and
joint destruction [9,10]. Studies in TNF receptor knock-
out mice have demonstrated that the incidence and
severity of collagen arthritis were less in such mice.
However, once the joints were affected, full progression
to erosive damage was seen in an apparently TNF-inde-
pendent fashion [11].
Similar studies with neutralizing antibodies have been
performed in a range of arthritis models. The relative
roles of TNF and IL-1 in early joint inflammation were
variable in different models, but the crucial role of IL-1 in
late arthritis and erosive joint destruction was a consis-
tent finding. This implies that overkill by other mediators
might occur in the inflammatory process, and that the
stimulus, type of process and probably also the stage of
the arthritis are major determinants of the mediator
profile. Intriguingly, IL-1 seems to be a suitable down-
stream target in joint erosion (see below).
Clinical trials with anti-TNF/anti-IL-1
In addition to the evidence from studies on animal
models, the cytokines TNF and IL-1 were demonstrated
in increased quantities in RA synovial tissue, along with
the presence of cell-associated receptors for these
cytokines [12]. The remarkable anti-inflammatory activity
of a first neutralizing monoclonal anti-TNF antibody in RA
patients revealed the potential of anti-cytokine therapy
[12] and has subsequently stimulated the development
of improved anti-TNF reagents such as fully humanized
antibody and engineered fusion proteins of TNF soluble
receptors and Fc fragments, with reduced immunogenic-
ity and a prolonged half-life. There is no doubt that TNF
blockers provide impressive protection against pain and
joint swelling in most RA patients [12–19]. It is also
evident that anti-TNF therapy is not effective in all RA
patients, nor does it control arthritis in all affected joints
of good responders.
The initial studies targeting IL-1 were performed with
soluble IL-1 type I receptor. Clinically relevant effects
were not seen, which was disappointing at the time and
raised questions about the relevance of IL-1 as a thera-
peutic target in human RA [20]. However, it is now
understood that the choice of type I receptor was unfor-
tunate because this soluble receptor has a high affinity
for IL-1 receptor antagonist (IL-1ra), thus scavenging the
endogenous IL-1 inhibitor. In that sense, the decoy
type II receptor might make a better inhibitor, but it has
the disadvantage that it has a lower affinity for IL-1.
Studies are awaited with optimal, engineered IL-1 recep-
tor fragments or potent, neutralizing anti-IL-1 antibodies.
Apart from studies with soluble receptors, clinical trials
have also employed IL-1ra, the effect on joint inflamma-
tion being limited. A significant reduction of joint erosion
was evident [21,22]. IL-1ra has a weak pharmacokinetic
profile and it is still unclear whether the limited effect on
joint inflammation is akin to the RA process or related to
suboptimal blocking of IL-1. Comparisons with animal
model studies teach us that continued high dosing is
crucial in fully controlling IL-1. Collagen arthritis could
not be controlled with a repeated daily injection of IL-1ra,
but great suppressive effects were achieved with IL-1ra
supplied with an osmotic minipump [9]. Similarly, local
IL-1ra overexpression in the knee joint with viral vectors
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showed proper efficacy in this model [23]. Until high-
quality IL-1 blockers become available for clinical trials,
conclusions on the relative roles of TNF and IL-1 in RA
patients have to be made with great care.
Anti-TNF treatment is anti-erosive?
Remarkably, the recent evaluation of joint erosions after
the treatment of RA patients with anti-TNF provided the
first evidence for a joint protective effect, as reported at
the 1999 ACR meeting. This was shown for a combina-
tion of anti-TNF antibodies with methotrexate, and also
for a single treatment with antibodies as well as TNF
soluble receptor. Unfortunately, the actual data have not
yet been published, hampering detailed attention in this
review. The finding might fit with the hypothesis that TNF
overproduction in RA synovial tissue is mainly caused by
deranged behaviour of synoviocytes, generating too
much TNF. If this is so, TNF will drive IL-1 production
and TNF blockade will be sufficient to control this
TNF–IL-1 pathway (Fig. 1). Intriguingly, it is in line with
the initial hallmark observation made in RA synovial cell
cultures: the addition of neutralizing anti-TNF antibodies
strikingly reduced the production of IL-1 [24]. Unfortu-
nately, this observation was made with isolated cell cul-
tures, has not been confirmed by others and awaits
confirmation for intact synovial tissue.
It is still too early to accept the above observations as
final proof of concept of a dominant TNF–IL-1 cascade
in RA synovial tissue. Anti-TNF antibodies used in clinical
studies display cytotoxic effects. This implies that one
mechanism of the anti-TNF effect could be linked to
binding to TNF-bearing cells and subsequent killing of
these cells, potentially including TNF/IL-1-producing
cells or neighbouring cells. In addition, the TNF soluble
receptor used in some of the anti-TNF trials not only
binds to TNF but also scavenges lymphotoxin. The latter
might have an impact on T-cell-driven pathways. Signifi-
cantly, TNF rather than lymphotoxin seems to be the
major cytokine expressed in RA synovial tissue. A final
comment to be made here is that analysis of anti-erosive
efficacy in clinical trials is based mainly on bone ero-
sions. Focal damage of cartilage is more difficult to
score on X-rays. It remains to be seen whether the rela-
tive dominance of TNF and IL-1 involvement and amplify-
ing elements by pathways mediated by T cells and
immune complexes are similar or different in the destruc-
tion of cartilage and bone in RA (see below).
Heterogeneous synovial cytokine patterns in
RA patients
Synovial biopsies taken from knee joints of RA patients and
analysed for cytokine immunolocalization or mRNA levels
identified a rather variable pattern [25–30]. Although TNF
was abundantly present in some RA patients, TNF was
undetectable in half of the patients. This limited presence
of TNF might be interpreted as an explanation for the high
efficacy of anti-TNF treatment in most patients, because
the levels to be neutralized are low [27]. Alternatively, it
might be seen as evidence for considerable heterogeneity
of the RA process in different patients. The apparent
absence of TNF in some patients and the fact that anti-TNF
therapy is not efficacious in all RA patients argues for multi-
ple pathways. Moreover, the cytokine interplay might vary in
different stages of the process in the same patient;
repeated sampling in large groups of RA patients is
needed to shed more light on this issue.
Intriguingly, IL-1β was found in most RA synovial biopsies
[28]. In addition, interferon-γ levels were low but IL-17 was
prominent in many RA patients [31], arguing for a reconsid-
eration of T cell involvement. It seems obvious that future
therapy will consist of combination treatment, at least
involving both TNF and IL-1. It is tempting to speculate that
tailor-made cytokine-directed therapy will be applicable in
the near future, based on individual cytokine patterns.
Role of TNF and IL-1 in various animal models
of arthritis
Further insight into the relative roles of TNF and IL-1, as
well as the TNF dependence of IL-1 production under
various arthritogenic conditions, has emerged from the
efficacy of TNF and IL-1 blocking in a range of well-
defined experimental arthritis models (Table 1). The model
systems include nonimmune triggering of macrophages as
well as different mixtures of arthritogenic pathways driven
Figure 1
Simplified view of potential pathways of TNF overproduction.
Deranged synoviocyte-mediated TNF production might initiate a
TNF–IL-1 cascade. Note that general triggering of T cells or
macrophages, as studied in arthritis models, gives rise to both TNF
and IL-1, with considerable TNF-independent IL-1 production, and
skewing to IL-1 when immune complexes are used as the stimulus.
by T cells and immune complexes. Some crucial findings
with the specific TNF and IL-1 blockers have recently
been backed up with analyses of models in mice deficient
in TNF and IL-1β. The latter type of approach excludes
misinterpretations potentially linked to variability in the
blocking quality of the different neutralizing antibodies and
soluble receptors used in the experimental studies.
Macrophage-driven arthritis
The strongest TNF dependence of acute inflammation is
found when arthritis is induced locally with a phlogistic
trigger such as streptococcal cell wall fragments (SCWs) or
yeast particles (Zymosan), as observed in rats and mice. Ero-
sions are mild in this model but still develop after treatment
with anti-TNF antibodies; this observation has been strength-
ened by the high degree of erosions when such models
were induced in TNF-deficient mice [32,33]. Not surprisingly,
IL-1 levels were still high under these conditions, identifying
considerable TNF-independent IL-1 triggering. When repeat
injections with SCW were given, the inflammation became
partly dependent on IL-1, and erosions still developed in
TNF-deficient mice and were fully absent in IL-1β-deficient
mice. The repeated flare model became more dependent on
T cells and arthritis seemed markedly reduced in lympho-
toxin-deficient mice (WB van den Berg, unpublished data), in
line with findings in encephalomyelitis [34].
Mixed T cell and immune complex pathways
Collagen-induced arthritis and antigen-induced arthritis
(AIA) are models based on preimmunization with a carti-
lage-specific autoantigen or an exogenous protein, with
the generation of T cell reactivity and antibodies. The
onset of arthritis is a mixture of pathways driven by
immune complexes and T cells. In AIA the onset of arthritis
is vigorous and at best partly dependent on TNF and IL-1,
but the cartilage erosion and propagation of inflammation
are dependent on IL-1 [35–38]. In contrast, TNF is impor-
tant at the onset of collagen arthritis, but IL-1 blocking is
highly efficacious in this model both in the acute inflamma-
tory state and in the advanced erosive disease. In line with
this, IL-1ra-deficient DBA mice show enhanced suscepti-
bility to collagen-induced arthritis [39]. Apparently, T cells
are important mainly in the early stages, to support the
production of sufficient collagen type II autoantibody, and
the propagation is driven by immune complexes, showing
strong dependence on IL-1.
Immune complex arthritis
A remarkable finding was the strong IL-1 dependence of
the inflammatory response induced with plain immune com-
plexes [40]. Recently, a novel autoimmune arthritis model
was generated in KRN mice by the transgenic overexpres-
sion of a T cell receptor directed against MHC (major
histocompatibility complex) molecules. This transgenic
condition resulted in a skewed control of tolerance and
was characterized by significant formation of autoanti-
bodies. The crucial observation was that the model was
transferable with purified autoantibodies, underlining the
arthritogenic potential of such a pathway [41,42]. Interest-
ingly, this model seemed to be dependent not on TNF but
on IL-1 (personal communication). An intriguing discussion
element is provided by the observation that small immune
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Table 1
Cytokine involvement in various experimental arthritis models
Cytokine involvement
Early inflammation Erosive arthritis
Arthritis Model Species References Principal target or trigger TNF IL-1 TNF IL-1
SCW-A Mouse [32] Macrophages ++ – – ++
SCW flare Mouse [33] T cells/macrophages + + – ++
SCW flare Rat [46,77] T cells/macrophages + + ++
AIA Mouse [35,36,38] T cells/IC ± ± ++
AIA Rabbit [37] T cells/IC + + ± ++
AIA flare Mouse [38] T cells ± + – ++
CIA Mouse [6–11] T cells/IC + ++ +* ++
ICA Mouse [40] IC – ++ – ++
AA Rat [45] T cells + + +* +
Cytokine involvement, based on experiments with neutralizing antibodies, started at the onset of arthritis. It does not reflect potential involvement
during preimmunization (CIA and AIA). SCW-A flares reflect the situation after three consecutive SCW flares with intervals of 7 days. AIA flare was
induced by antigen rechallenge at day 21. CIA, collagen-induced arthritis; ICA, passive immune complex (IC) arthritis. *Efficacy of anti-TNF
treatment only when started at onset of first signs of arthritis.
complexes tend to trigger RA synovial macrophages
through FcγIII receptors, resulting in TNF production and
scant production of IL-1α [43]. Unfortunately, IL-1β was
not analysed in this study. Comparative studies with differ-
ent subsets of immune complexes and macrophages with
different Fc receptor compositions are needed.
T-cell-driven arthritis
The classic model of adjuvant arthritis (AA) in rats is consid-
ered to be a pure T cell model, because the disease can be
easily transferred with T cells and T cell immunomodulation
greatly affects the course of AA. Recent studies have clearly
identified both TNF and IL-1 as crucial elements in this
model, because synergism was evident in combined treat-
ment with TNF soluble receptors and poly(ethylene glycol)-
treated IL-1ra [44,45]. Although there is no doubt that TNF
is an important cytokine in T cell maturation, blocking of IL-1
has added value. This is found not only in AA but also in the
T-cell-dependent exacerbations of smouldering SCW arthri-
tis or AIA, upon rechallenge with antigen [33,38,46].
Final remarks on animal models
Major conclusions are summarized in Table 1, and details
can be found in the references cited there. It is evident that
IL-1 is not necessarily a dominant cytokine in the acute,
inflammatory stages of most arthritis models but has a crucial
role in the propagation of joint inflammation and concomitant
cartilage and bone erosion in all models. IL-1α seems to act
in acute stages, but IL-1β is the crucial cytokine in advanced
stages [9], as underlined by the total absence of chronic
erosive arthritis in IL-1β-deficient mice. The fact that the
chronic, destructive stage is dependent on IL-1 and not on
TNF proves indirectly that TNF-independent IL-1 production
occurs under the experimental model conditions listed. This
holds not only for arthritis but also for similar conditions such
as encephalomyelitis [47]. If elements of the models apply to
the arthritic process in subsets of RA patients, it is necessary
to block IL-1β in addition to TNF.
Further support for the crucial role of IL-1 emerged from
the recent demonstration of spontaneous arthritis in
Balb/c mice, which are deficient in IL-1ra [48]. The occur-
rence of spontaneous arthritis, when the IL-1ra deficiency
was backcrossed to a Balb/c genetic background, illus-
trates the continued arthritogenic pressure of environmen-
tal stimuli, resulting in the generation of IL-1, which is
normally controlled by endogenous IL-1ra.
Remarkably, synovial cell density in chronic SCW arthritis
is even more pronounced in TNF-deficient mice than in
normal mice, suggesting a homeostatic role of TNF in the
control of synovial cell survival. Similar observations have
been made in infection models [49]. In synovial cell cul-
tures it is clear that TNF can activate cells through the
nuclear factor-κB (NF-κB) pathway but can also con-
tribute to apotosis. This might imply that full TNF blockade
should be avoided in therapeutic approaches. An elegant
therapeutic alternative is to block the NF-κB pathway [50],
still maintaining the TNF-induced regression of cell
growth. Apart from TNF, Fas is involved in cell death and
TNF interferes with Fas-mediated apoptosis [51], compli-
cating the net outcome of TNF blockade. Recent studies
identified a role of TNF-related apoptosis-inducing ligand
(TRAIL) in the suppression of autoimmune inflammation
[52]. It remains to be seen to what extent the various path-
ways are touched by anti-TNF therapy. In that sense, the
inhibition of IL-1 seems safer because IL-1 is not required
for normal homeostasis [53].
For further reading on animal models the review by
Klareskog is recommended [54], in which elements of the
possible absence of specific immune reactions in RA are
discussed. It has been shown that impaired on/off regula-
tion of TNF biosynthesis in mice induces pathologies in
joints [55], but evidence that similar disregulation occurs in
RA patients is still lacking. An interesting approach to
obtaining further insight into possible stimuli or derange-
ments in the RA process is the analysis of signalling path-
ways turned on in RA synovial cells, to see whether this fits
with pathways of known stimuli [56]. However, a serious
problem encountered is the fact that pathways are depen-
dent on the maturation stage and receptor expressions of
cells; the isolation and subsequent culturing of cells skews
their characteristics. Differential gene expression analysis
on freshly isolated pieces of synovial tissue might offer an
alternative, although first studies in RA synovial tissue have
already identified substantial heterogeneity.
Cartilage erosion
Destruction of articular cartilage is caused by the combi-
nation of inhibited synthetic activity of the articular chon-
drocytes and enzymic breakdown of the matrix. The latter
can be elicited by enzymes released from chondrocytes
and/or the inflamed synovial tissue, in particular at sites of
so-called pannus overgrowth of the cartilage. Transfer
studies in SCID (severe combined immunodeficiency)
mice demonstrated the invasive and destructive character
of RA synovial cells, and gene transfer studies with
cytokine inhibitors identified that TNF was marginally
involved in invasion, yet IL-1 was crucial in chondrocyte
activation and matrix destruction [57,58].
Early cartilage damage is characterized by a loss of proteo-
glycans, which in principle is a reversible process. A major
step in erosive tissue loss is the destruction of collagen
bundles. Intriguingly, IL-1 is very potent in inducing the sup-
pression of matrix synthesis by the chondrocytes. It also
induces the release of active aggrecanase, which is the
dominant enzyme responsible for proteoglycan loss. In con-
trast, IL-1 induces the release of latent forms of matrix met-
alloproteinases (MMPs), including stromelysin (MMP-3)
and collagenase (MMP-13). The latter is crucial in collagen
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breakdown; stromelysin seems to be pivotal in the activa-
tion of collagenase [59–61]. IL-1 alone gives limited carti-
lage erosions, linked to moderate autoactivation of MMPs.
Elements that might enhance the erosive character are
cytokine autoinduction in the chondrocytes, with autocrine
and paracrine effects on neighbouring chondrocytes, the
upregulation of cytokine receptors on these cells, the pres-
ence of immune complexes in the cartilage surface, and
T-cell-derived IL-17 (Fig. 2). IL-1 and TNF production by
arthritic chondrocytes has been demonstrated, and TNF
receptor upregulation is evident in osteoarthritic cartilage
[62,63]. In the presence of immune complexes in the joint,
IL-1-induced latent MMPs become broadly activated and
cause major tissue erosion [64]. Fc receptor binding on
leucocytes and/or chondrocytes and the release of activat-
ing enzymes are crucial elements in this activation step
mediated by immune complexes. Cartilage erosion is
absent in antigen-induced arthritis elicited in mice deficient
in Fc receptor, despite florid joint inflammation [65]. In
addition, IL-1ra treatment prevents erosions and MMP
activity in this model, with limited suppression of acute joint
inflammation [60]. These findings identify IL-1 as a pivotal
initiating step in erosive processes and underline the role of
immune complexes in the exaggeration of destruction.
Rheumatoid factor positivity is correlated with more severe
and destructive forms of RA, which might fit with the above
concept. Apart from immune complexes, T-cell-derived
factors might enhance cartilage damage. Interferon-γ has
been shown to synergize with TNF and IL-1 in chondrocyte
activation [66]; more recently, IL-17 showed direct chon-
drocyte-mediated cartilage damage, in common with IL-1
[67,68]. Interestingly, IL-17 levels are high in RA synovial
fluid [68].
Bone erosion
Apart from cartilage damage, chronic arthritis is character-
ized by erosions of the underlying bone. The recently iden-
tified osteoprotegerin ligand (OPG-L) seems to be a
crucial mediator in this process [69–71], because bone
loss was absent in OPG-L deficient mice. OPG-L is the
pivotal mediator of osteoclast differentiation and activa-
tion; it triggers the cells through RANK (receptor activator
of NF-κB). Its production can be stimulated by a range of
cytokines. IL-1 is the most potent activator and is also a
dominant factor in osteoclast differentiation. TNF and
IL-17 are less potent but display considerable synergy in
osteoclastic bone resorption [72], suggesting that TNF is
a crucial factor, along with IL-17, at sites of activated
T cells. It remains to be identified whether OPG-L is a
good target for the prevention of bone erosion or whether
it is safer to target the inducing and modulating cytokines.
An obvious side effect of the direct blocking of OPG-L is
unwanted interference with normal turnover of bone. Interest-
ingly, it is claimed that TNF can stimulate osteoclast differen-
tiation by a mechanism independent of RANK [73], which
might fit with a direct anti-erosive effect of anti-TNF treatment
in RA patients. Apart from effects on osteoclasts, it is evident
that the cytokines IL-1, TNF and IL-17 have an effect on
osteoblasts, potentially complicating the net effect of anti-
cytokine treatment on bone production and resorption.
Conclusions
This review has focused on TNF and IL-1, in line with a key
role for these cytokines and the therapeutic applicability of
specific inhibitors. It is necessary to block IL-1β in addition
to TNF. Apart from suppression of arthritogenic mediators,
an alternative approach is to apply modulatory cytokines
such as IL-4 and IL-10. In addition, IL-6, IL-12 and proba-
bly also IL-15 and IL-18 [74–76] might prove to be valu-
able targets in chronic destructive arthritis. A detailed
discussion is beyond the scope of this review.
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